Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel J Waters

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|November 2, 2021
Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7Jason J Marineau, Kristin B Hamman, Shanhu Hu, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool CompoundLorna H Mitchell, Allison E Drew, Scott A Ribich, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666Kenneth W Duncan, Nathalie Rioux, P Ann Boriack-Sjodin, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Biopharmaceutics & Drug Disposition|January 14, 2014
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitorAravind Basavapathruni, Edward J Olhava, Scott R Daigle, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Scientific Reports|December 23, 2017
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E Drew, Oscar Moradei, Suzanne L Jacques, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|November 2, 2021
Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7Jason J Marineau, Kristin B Hamman, Shanhu Hu, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool CompoundLorna H Mitchell, Allison E Drew, Scott A Ribich, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666Kenneth W Duncan, Nathalie Rioux, P Ann Boriack-Sjodin, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Biopharmaceutics & Drug Disposition|January 14, 2014
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitorAravind Basavapathruni, Edward J Olhava, Scott R Daigle, et al.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Scientific Reports|December 23, 2017
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E Drew, Oscar Moradei, Suzanne L Jacques, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Pageof 5